Table 2.
Real-world treatment pattern and baseline characteristics of Endostar plus different chemotherapy in treatment-naïve and re-treatment patients.
| Variables | Treatment-naï ve patients (N = 417) | Re-treatment patients (N = 95) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Endostar plus NP | Endostar plus DP | Endostar plus GP | Endostar plus PP | Endostar plus TP | Endostar plus NP | Endostar plus DP | Endostar plus GP | Endostar plus PP | Endostar plus TP | |
| N (%) | 26 (6.24) | 54 (12.95) | 148 (35.49) | 122 (29.26) | 67 (16.07) | 27 (28.42) | 25 (26.32) | 18 (18.95) | 14 (14.74) | 11 (11.58) |
| Age, years | ||||||||||
| Mean ± SD | 57.2 ± 7.0 | 57.8 ± 10.2 | 59.5 ± 9.5 | 56.4 ± 11.6 | 59.8 ± 9.2 | 56.8 ± 9.3 | 58.0 ± 8.4 | 57.5 ± 7.0 | 56.9 ± 12.2 | 57.4 ± 9.6 |
| Median (Q1-Q3) | 57.2 (52.4–61.4) | 58.9 (49.4–66.5) | 50.7 (53.6–66.7) | 56.4 (49.4–66.5) | 58.9 (49.4–66.5) | 55.0 (48.8–52.6) | 58.0 (52.4–64.3) | 57.6 (52.8–59.1) | 57.8 (45.4–63.1) | 56.5 (49.8–55.4) |
| Sex, n (%) | ||||||||||
| Unknown | 2 (7.7) | 2 (3.7) | 5 (3.4) | 1 (0.8) | 4 (6.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Male | 17 (65.4) | 38 (70.4) | 131 (88.5) | 76 (62.3) | 54 (80.6) | 18 (66.7) | 17 (68.0) | 15 (83.3) | 10 (71.4) | 9 (81.8) |
| Female | 7 (26.9) | 14 (25.9) | 12 (8.1) | 45 (36.9) | 9 (13.4) | 9 (33.3) | 8 (32.0) | 3 (16.7) | 4 (28.6) | 2 (18.2) |
| Smoking history | ||||||||||
| No | 10 (38.5) | 22 (40.7) | 38 (25.7) | 63 (51.6) | 12 (17.9) | 14 (51.9) | 9 (36.0) | 6 (33.3) | 7 (50.0) | 4 (36.4) |
| Yes | 16 (61.5) | 32 (59.3) | 110 (74.3) | 59 (48.4) | 55 (82.1) | 13 (48.2) | 16 (64.0) | 12 (66.7) | 7 (50.0) | 7 (63.6) |
| Family history of lung cancer | ||||||||||
| No | 26 (100.0) | 54 (100.0) | 145 (98.0) | 117 (95.9) | 61 (91.0) | 25 (92.6) | 23 (92.0) | 18 (100.0) | 14 (100.0) | 10 (90.9) |
| Yes | 0 | 0 | 3 (2.0) | 5 (4.1) | 6 (9.0) | 2 (7.4) | 2 (8.0) | 0 | 0 | 1 (9.1) |
| Disease stage | ||||||||||
| III | 12 (46.2) | 21 (38.9) | 75 (50.7) | 17 (13.9) | 28 (41.8) | 9 (33.3) | 12 (48.0) | 8 (44.4) | 4 (28.6) | 2 (18.2) |
| IV | 14 (53.9) | 33 (61.1) | 73 (49.3) | 105 (86.1) | 39 (58.2) | 18 (66.7) | 13 (52.0) | 10 (55.6) | 10 (71.4) | 9 (81.8) |
| Pathological type | ||||||||||
| Squamous cell carcinoma | 8 (30.8) | 23 (42.6) | 88 (59.5) | 3 (2.5) | 18 (26.9) | 12 (44.4) | 13 (52.0) | 11 (61.1) | 3 (21.4) | 2 (18.2) |
| Adenocarcinoma | 5 (19.2) | 27 (50.0) | 5 (3.4) | 107 (87.7) | 18 (26.9) | 14 (51.9) | 10 (40.0) | 3 (16.7) | 9 (64.3) | 7 (63.6) |
| Unknown | 11 (42.3) | 1 (1.9) | 55 (37.2) | 11 (9.0) | 31 (46.3) | 1 (3.7) | 2 (8.0) | 4 (22.2) | 1 (7.1) | 1 (9.1) |
| Other | 2 (7.7) | 3 (5.6) | 0 (0) | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 1 (9.1) |